4//SEC Filing
DeLong Mark Jeffrey 4
Accession 0001127602-25-001616
CIK 0001492422other
Filed
Jan 20, 7:00 PM ET
Accepted
Jan 21, 3:59 PM ET
Size
6.2 KB
Accession
0001127602-25-001616
Insider Transaction Report
Form 4
DeLong Mark Jeffrey
Chief Business & Strat Officer
Transactions
- Sale
Common Stock
2025-01-17$29.96/sh−1,235$36,998→ 57,561 total - Award
Common Stock
2025-01-21+28,508→ 86,069 total
Footnotes (2)
- [F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 16, 2025.
- [F2]This represents a Restricted Stock Unit award granted on January 21, 2025 that vest 25% annually over four years from grant date subject to continued service.
Documents
Issuer
Apellis Pharmaceuticals, Inc.
CIK 0001492422
Entity typeother
Related Parties
1- filerCIK 0001856078
Filing Metadata
- Form type
- 4
- Filed
- Jan 20, 7:00 PM ET
- Accepted
- Jan 21, 3:59 PM ET
- Size
- 6.2 KB